Industry Strength Score
32/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
NERVGEN PHARMA CORP (NGEN) Stock Price & Overview
NASDAQ:NGEN • CA64082X2032
Current stock price
3.78 USD
+0.15 (+4.13%)
Last:
The current stock price of NGEN is 3.78 USD. Today NGEN is up by 4.13%. In the past month the price decreased by -11.27%.
NGEN Key Statistics
1-Month Range3.6 - 4.67
Current NGEN stock price positioned within its 1-month range.
- Market Cap
- 304.441M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.28
- Dividend Yield
- N/A
NGEN Stock Performance
Today
+4.13%
1 Week
-3.57%
1 Month
-11.27%
3 Months
-5.74%
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
NGEN Stock Chart
NGEN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NGEN.
Chartmill TA Rating
Chartmill Setup Rating
NGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NGEN. NGEN has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NGEN Earnings
On March 31, 2026 NGEN reported an EPS of -0.06 and a revenue of 77.07K. The company beat EPS expectations (0.99% surprise).
Next Earnings DateMay 14, 2026
Last Earnings DateMar 31, 2026
PeriodQ3 / 2025
EPS Reported-CA$0.06
Revenue Reported77.07K
EPS Surprise 0.99%
Revenue Surprise %
NGEN Forecast & Estimates
8 analysts have analysed NGEN and the average price target is 5.7 USD. This implies a price increase of 50.77% is expected in the next year compared to the current price of 3.78.
Analysts
Analysts80
Price Target5.7 (50.79%)
EPS Next Y24.97%
Revenue Next YearN/A
NGEN Financial Highlights
Over the last trailing twelve months NGEN reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS increased by 2.11% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-25.82M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -197.42% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%14.29%
Sales Q2Q%N/A
EPS 1Y (TTM)2.11%
Revenue 1Y (TTM)N/A
NGEN Ownership
Ownership
Inst Owners0.06%
Shares80.54M
Float63.62M
Ins Owners2.72%
Short Float %2%
Short Ratio7.67
NGEN Industry Overview
NGEN operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 29 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
48/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
32%
Outperformed 32% of sub-industries
3 Month Rank
63%
Outperformed 63% of sub-industries
6 Month Rank
26%
Outperformed 26% of sub-industries
Industry Fundamentals & Breadth
- Members
- 29
- New Highs
- 3.5%
- New Lows
- 10.3%
- Average ROE
- 17.5%
- Average Profit Margin
- 9.9%
- Average Operating Margin
- 19%
- Average P/E
- 5.2
- Average Fwd P/E
- 17.7
- Average Debt/Equity
- 0.5
NGEN Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.63 | 883.029B | ||
| JNJ | JOHNSON & JOHNSON | 17.91 | 553.619B | ||
| MRK | MERCK & CO. INC. | 11.43 | 269.662B | ||
| PFE | PFIZER INC | 8.81 | 151.879B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 123.709B | ||
| ZTS | ZOETIS INC | 16.14 | 48.347B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.899B | ||
| VTRS | VIATRIS INC | 6.03 | 17.396B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.39 | 11.171B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.626B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.971B | ||
| CORT | CORCEPT THERAPEUTICS INC | 35.54 | 4.948B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NGEN
Company Profile
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Company Info
IPO: 2019-03-13
NERVGEN PHARMA CORP
Suite 1703 - 595 Burrard Street
Vancouver BRITISH COLUMBIA CA
Employees: 7
Phone: 16047225361
NERVGEN PHARMA CORP / NGEN FAQ
What does NERVGEN PHARMA CORP do?
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
What is the stock price of NERVGEN PHARMA CORP today?
The current stock price of NGEN is 3.78 USD. The price increased by 4.13% in the last trading session.
Does NERVGEN PHARMA CORP pay dividends?
NGEN does not pay a dividend.
What is the ChartMill technical and fundamental rating of NGEN stock?
NGEN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is NERVGEN PHARMA CORP (NGEN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NGEN.
What is the market capitalization of NGEN stock?
NERVGEN PHARMA CORP (NGEN) has a market capitalization of 304.44M USD. This makes NGEN a Small Cap stock.